Exagen Inc.

As of June 30, 2026, Exagen, Inc. carries a market capitalization of 100.16M, placing it among publicly traded companies globally. Its enterprise value stands at 101.43M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Exagen, Inc.'s next confirmed earnings release is scheduled for November 16, 2026.

As of June 30, 2026, Exagen, Inc. has 24.19M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 1.57, and the price-to-book ratio stands at 9.37.

These figures are as of June 30, 2026. The EV/Sales ratio of 1.63 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 101.43M versus a market cap of 100.16M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Exagen, Inc. maintains a current ratio of 3.18, meaning it holds 3.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 213.15, indicating elevated leverage, while an interest coverage ratio of -2.11 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Exagen, Inc. posted a negative return on equity (ROE) of -113.82, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -34.19, reflecting losses generated across the asset base. The company generates approximately 290,562.83 in revenue per employee across its workforce of 214.25, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Exagen, Inc. recorded 43,765.00 in income tax expense. The company reported a pretax loss of -16.52M and -16.56M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Exagen, Inc.'s stock has declined approximately 34.65% over the past 52 weeks. The 50-day moving average sits at 6.83, while the 200-day moving average is 4.32.

Over the twelve months ended June 30, 2026, Exagen, Inc. generated 62.25M in revenue and converted that into -16.56M in net income, yielding earnings per share of -0.70. EBITDA reached -9.43M, while operating income came in at -11.56M.

As of June 30, 2026, Exagen, Inc. holds 21.52M in cash and equivalents against 22.79M in total debt, resulting in a net debt position of -1.53M. Total book value stands at 10.69M, with working capital of 25.73M providing operational flexibility.

Exagen, Inc. produced -5.69M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -954,077.00 in capital expenditures, free cash flow totaled -6.64M - equivalent to -0.28 per share.

Over the twelve months ended June 30, 2026, Exagen, Inc. posted a gross margin of 58.64, reflecting its pricing power and cost economics. The operating margin of -18.58 and net profit margin of -26.61 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -6.79: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -1.86, meaning Exagen, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Exagen, Inc. has an Altman Z-Score of -5.73, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.